ARTICLE | Clinical News
Tumor Necrosis Therapy regulatory update
February 14, 2000 8:00 AM UTC
TCLN received U.S. Patent No. 6,017,514 covering its TNT technology, which uses antibodies that bind to dead or decaying cells at the center of tumors, as a cancer imaging agent. ...